Loading
Latest filing published 22 Aug 2023 for Virios Therapeutics, Inc., €18k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of William Pridgen in Dogwood Therapeutics, Inc., where the filings describe the role as board member. In total, 12 filings cover trades dated from 17 December 2020 to 21 August 2023.
No open-market sale appears; the market trades are 11 purchases worth €207k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 option exercise. So far in 2023, the count stands at 1 purchase and no sales.
The median purchase comes to €15k. 6 out of 11 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The latest filing, published on 22 August 2023, reports an open-market purchase of €18k in Dogwood Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations